Published in Blood on April 25, 2014
HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4. AIDS (2015) 0.76
Approach to chemotherapy-associated thrombosis. Vasc Med (2015) 0.75
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
LKLF: A transcriptional regulator of single-positive T cell quiescence and survival. Science (1997) 3.77
KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med (2004) 3.69
Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res (2005) 2.45
KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood (2006) 2.41
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A (2006) 1.95
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol (2006) 1.65
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA (2006) 1.59
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res (2010) 1.47
Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest (2012) 1.46
The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity (2011) 1.39
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol (2008) 1.34
The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther (2004) 1.17
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol (2009) 1.11
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost (2006) 1.02
Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function. Am J Physiol Heart Circ Physiol (2013) 1.01
Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors. Arterioscler Thromb Vasc Biol (2009) 0.99
Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol (2013) 0.94
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia. Stroke (2010) 0.93
Platelet-monocyte interactions--a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem (2008) 0.89
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res (2007) 0.88
Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost (2004) 0.85
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica (2008) 0.81